Siemens Medical Solutions' Artis zeego features a multi-axis C-arm that employs robotic technology to extend imaging capabilities through virtually unrestricted C-arm positioning.
System use reportedly results in advanced cross-sectional imaging via its positioning flexibility, which reportedly is not achievable with traditional C-arm systems. The Artis zeego allows the position of the isocenter to be adjusted according to the procedural needs or the height of the physician. The adjustable isocenter also enables off-center rotational angiography for all areas of the body and supports advanced 3D imaging techniques, including cross-sectional imaging through Siemens' first-to-market syngo DynaCT.
The Artis zeego's design reportedly enables advanced imaging capabilities, such as large-volume syngo DynaCT scans, which enable the physician to see the whole abdomen or the entire liver for chemoembolization and biopsies. The system also addresses neuro-interventional challenges by offering views of the skull and the neck and expanded views of the spine.
The Artis zeego is accompanied by Artis zee, a family of interventional imaging systems reportedly designed to offer breakthrough versatility, enhanced image quality and streamline workflow across an array of clinical environments, from body and neuro-interventional radiology suites to operating rooms and hybrid rooms.
Enhanced 3D imaging applications featured with the Artis zee systems include: syngo iPilot, which reportedly enables faster, more precise catheter navigation through 3D roadmapping that superimposes 3D reconstructions onto live 2D fluoroscopy images, 2D roadmaps or digital subtraction angiography (DSA). The application provides real-time updates of C-arm and table movements, as well as zoom and source-to-image distance (SID) changes. The Artis zee systems also include syngo iGuide, which brings needle procedures back into the interventional suite, enabling enhanced comfort for the physician and freeing up the computed tomography (CT) scanner from this lengthy procedure, according to the company.
September 19, 2023 
